SPRY ARS Pharmaceuticals, Inc.

NASDAQ
$2.65

ARS Pharmaceuticals, Inc. (SPRY) is confirmed to report earnings on November 5, 2026, after the market close. The consensus earnings estimate is a loss of $0.35 per share.

ARS Pharmaceuticals, Inc. Missed Consensus Estimates
Thursday, November 5, 2026 · 4:01 PM ET
Earnings Date
4th Quarter, Dec 2026
Nov 5
Thursday · 4:00 PM ET
Earnings Whisper
-
vs ($0.35)
Volatility
Enter your expectations below to reveal the current volatility.
Trend Analysis
Expectation
Earnings
Price action
Signals
Score
Sentiment
Grade
Life Cycle
Call Analysis
Earnings-AVWAP $4.58

Sign in or subscribe to unlock sentiment, short interest, and technical indicators.

About ARS Pharmaceuticals, Inc.

ARS Pharmaceuticals is a biopharmaceutical company dedicated to empowering at-risk patients and their caregivers to better protect patients from allergic reactions that could lead to anaphylaxis.

Sector

Healthcare

Industry

Drug Manufacturers/Other

Held By 1 ETFs, by dollar flow

Charts powered in part by Lightweight Charts™ by TradingView.